Chemopreventive efficacy of stampidine in a murine breast cancer model

References

• Venkatachalam TK, Goodman PA, Qazi S, et al. Rational drug design of multifunctional phosphoramidate substituted nucleoside analogs. Curr Pharm Des. 2004;10(15):1713–1726.
   PubMed Web of Science ®Google Scholar
• Iyer VV, Griesgraber GW, Radmer MR, et al. Synthesis, in vitro anti-breast cancer activity, and intracellular decomposition of amino acid methyl ester and alkyl amide phosphoramidate monoesters of 3ʹ-azido-3ʹ-deoxythymidine (AZT). J Med Chem. 2000;43(11):2266–2274.
   PubMed Web of Science ®Google Scholar
• Wu W, Sigmond J, Peters GJ, et al. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J Med Chem. 2007;50(15):3743–3746.
   PubMed Web of Science ®Google Scholar
• Lewandowska M, Ruszkowski P, Chojnacka K, et al. Synthesis and anticancer activity of some 5-fluoro-2ʹ-deoxyuridine phosphoramidates. Bioorg Med Chem. 2016;24(10):2330–2341.
   PubMed Web of Science ®Google Scholar
• Coyne CP, Narayanan L. Gemcitabine-(5ʹ-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549). Chem Biol Drug Des. 2017;89(3):379–399.
   PubMed Web of Science ®Google Scholar
• Yoon JS, Jarhad DB, Kim G, et al. Design, synthesis and anticancer activity of fluorocyclopentenyl-purines and - pyrimidines. Eur J Med Chem. 2018;155:406–417.
   PubMed Web of Science ®Google Scholar
• Thornton PJ, Kadri H, Miccoli A, et al. Nucleoside phosphate and phosphonate prodrug clinical candidates. J Med Chem. 2016;59(23):10400–10410.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Tai HL, D’Cruz OJ. Antileukemic activity and cellular metabolism of the aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07). Arzneimittelforschung. 2005;55(1):50–65.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Chen CL, Liu XP, et al. In vitro and in vivo pharmacokinetic features and metabolism of the novel cytotoxic nucleoside analog 3ʹ-azidothymidine 5ʹ-[p-methoxyphenylmethoxyalaninyl phosphate] (Compound 003). Arzneimittelforschung. 2004;54(11):732–745.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Vassilev AO, Dibirdik I, et al. Anti-cancer activity profile of 3ʹ-azidothymidine 5ʹ-[p-methoxyphenylmethoxyalaninyl phosphate] (Compound 003), a novel nucleoside analog. Arzneimittelforschung. 2004;54(11):715–731.
   PubMed Web of Science ®Google Scholar
• Blagden SP, Rizzuto I, Suppiah P, et al. Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. Br J Cancer. 2018;119(7):815–822.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Cahn P, Qazi S, et al. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Expert Opin Investig Drugs. 2012;21(4):489–500.
   PubMed Web of Science ®Google Scholar
• Cahn P, Rolon MJ, Gun AM, et al. Preclinical and first-in-human phase I clinical evaluation of stampidine, a potent anti-HIV. J AIDS Clinic Res. 2012;3:138.
   Google Scholar
• Qazi S, Uckun F. Stampidine as a potent epigenetic silencer of host HIV dependency factor genes in HIV-infected cells. J AIDS Clinic Res. 2012;3:147.
   Google Scholar
• Fukui M, Yamabe N, Zhu BT. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer. 2010;46(10):1882–1891.
   PubMed Web of Science ®Google Scholar
• Hua F, Li K, Yu JJ, et al. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations. Nat Commun. 2015;6:7951.
   PubMed Web of Science ®Google Scholar
• Sahin K, Tuzcu M, Sahin N, et al. Inhibitory effects of combination of lycopene and genistein on 7,12- dimethyl benz(a)anthracene-induced breast cancer in rats. Nutr Cancer. 2011;63(8):1279–1286.
   PubMed Web of Science ®Google Scholar
• Jarzabek K, Koda M, Kozlowski L, et al. The significance of the expression of ERRalpha as a potential biomarker in breast cancer. J Steroid Biochem Mol Biol. 2009;113:127–133.
   PubMed Web of Science ®Google Scholar
• Taheri M, Omrani MD, Noroozi R, et al. Retinoic acid-related orphan receptor alpha (RORA) variants and risk of breast cancer. Breast Dis. 2017;37(1):21–25.
   PubMedGoogle Scholar
• Yuedi D, Yuankun C, Jiaying Z, et al. TFCP2 activates beta-catenin/TCF signaling in the progression of pancreatic cancer. Oncotarget. 2017;8(41):70538–70549.
   PubMedGoogle Scholar
• Santhekadur PK, Rajasekaran D, Siddiq A, et al. The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. Am J Cancer Res. 2012;2:269–285.
   PubMed Web of Science ®Google Scholar
• Jiang H, Du J, Jin J, et al. LSF expression and its prognostic implication in colorectal cancer. Int J Clin Exp Pathol. 2014;7:6024–6031.
   PubMed Web of Science ®Google Scholar
• Yonemori K, Seki N, Kurahara H, et al. ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA 375 in pancreatic ductal adenocarcinoma. Cancer Sci. 2017;108:124–135.
   PubMed Web of Science ®Google Scholar
• Dandekar S, Sukumar S, Zarbl H, et al. Activation of the cellular Harvey-ras oncogene in dimethylbenzanthracene-induced mouse mammary tumors. Mol Cell Biol. 1986;6:4104–4108.
   PubMed Web of Science ®Google Scholar
• Waldmann V, Suchy B, Rabes HM. Cell proliferation and prevalence of ras gene mutations in 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. Res Exp Med. 1993;193:143–151.
   PubMedGoogle Scholar
• Rochlitz CF, Scott GK, Dodson JM, et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res. 1989;49:357–360.
   PubMed Web of Science ®Google Scholar